Credit Agricole’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-134,213
Closed -$13.7M 1129
2024
Q1
$13.7M Sell
134,213
-310,169
-70% -$31.3M 0.15% 114
2023
Q4
$44.2M Buy
444,382
+411,882
+1,267% +$34.6M 0.5% 40
2023
Q3
$3.36M Buy
32,500
+20,000
+160% +$2.23M 0.05% 234
2023
Q2
$1.52M Buy
+12,500
New +$1.67M 0.03% 265
2022
Q3
Sell
-10,000
Closed -$1.43M 705
2022
Q2
$1.43M Hold
10,000
0.04% 275
2022
Q1
$1.72M Buy
+10,000
New +$1.68M 0.03% 263

Other funds holding MRNA

Credit Agricole's MRNA Position: Q1 2026 in Review

Credit Agricole reduced its Moderna (MRNA) stake by 7.9% in Q1 2026, selling an estimated $806K and leaving 200,797 shares worth $10.2M. The position accounts for 0.03% of the portfolio, ranked #393.

Credit Agricole first reported a position in MRNA in Q1 2020 and has held it in 23 quarters since. The position peaked at $23.1M in Q4 2023. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Credit Agricole held 200,797 shares of Moderna worth $10.2M as of Q1 2026.
  • Credit Agricole sold 17,266 Moderna shares in Q1 2026, an estimated $806K.
  • Moderna made up 0.03% of Credit Agricole's portfolio in Q1 2026, its #393 holding.
  • Credit Agricole first reported a position in Moderna in Q1 2020 and has held it in 23 quarters since.
  • Credit Agricole's Moderna position peaked at $23.1M in Q4 2023.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Credit Agricole's 13F filing for Q1 2026, filed 15 May 2026.